These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14641861)

  • 21. Effectiveness of fludarabine- and busulfan-based conditioning regimens in patients with acute myeloblastic leukemia: 8-year experience in a single center.
    Kasar M; Asma S; Kozanoglu I; Maytalman E; Boga C; Ozdogu H; Yeral M
    Transplant Proc; 2015 May; 47(4):1217-21. PubMed ID: 26036558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential for transfusion-associated graft-versus-host disease due to apheresis platelets matched for HLA class I antigens.
    Grishaber JE; Birney SM; Strauss RG
    Transfusion; 1993; 33(11):910-4. PubMed ID: 8259596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
    Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
    Gupta V; Ball SE; Sage D; Ortin M; Freires M; Gordon-Smith EC; Marsh JC
    Bone Marrow Transplant; 2005 Mar; 35(5):467-71. PubMed ID: 15665848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fludarabine-based reduced intensity regimen for matched related donor hematopoietic stem cell transplantation in acquired severe aplastic anemia.
    Ghanem KM; Kharfan-Dabaja MA; El-Solh H; Harris N; Kreidieh N; Nehme R; Muwakkit SA; Saab R; Bazarbachi A; Abboud MR
    Curr Res Transl Med; 2017 Sep; 65(3):115-119. PubMed ID: 28988743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Outcome With Fludarabine-Based Conditioning Regimen for Hematopoietic Stem Cell Transplantation From Related Donor in Fanconi Anemia: A Single Center Experience From Turkey.
    Kuşkonmaz B; Ünal Ş; Bayhan T; Aytaç Eyüboğlu S; Tavil B; Çetin M; Gümrük F; Uçkan Çetinkaya D
    Pediatr Blood Cancer; 2016 Apr; 63(4):695-700. PubMed ID: 26703084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
    Tan PL; Wagner JE; Auerbach AD; Defor TE; Slungaard A; Macmillan ML
    Pediatr Blood Cancer; 2006 May; 46(5):630-6. PubMed ID: 16078221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
    Kumar R; Prem S; Mahapatra M; Seth T; Chowdhary DR; Mishra P; Pillai L; Narendra AM; Mehra NK; Saxena R; Choudhry VP
    Bone Marrow Transplant; 2006 Apr; 37(8):745-9. PubMed ID: 16518427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation.
    Mattsson J; Uzunel M; Brune M; Hentschke P; Barkholt L; Stierner U; Aschan J; Ringdén O
    Br J Haematol; 2001 Dec; 115(4):935-44. PubMed ID: 11843830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Audit of peripheral stem cell transplantation for aplastic anemia in multitransfused infected patients.
    Seth T; Kanga U; Sood P; Sharma V; Mishra P; Mahapatra M
    Transplant Proc; 2012 May; 44(4):922-4. PubMed ID: 22564586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
    Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor.
    Ryo R; Saigo K; Hashimoto M; Kohsaki M; Yasufuku M; Watanabe N; Okada M; Tadokoro K; Juji T
    Vox Sang; 1999; 76(4):241-6. PubMed ID: 10394145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
    Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
    Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin.
    Grosskreutz C; Scigliano E; Osman K; Isola L
    Transplantation; 2007 Sep; 84(5):598-604. PubMed ID: 17876272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
    Massenkeil G; Nagy M; Le Coutre P; Heine F; Rosen O; Dörken B; Arnold R
    Hematol J; 2004; 5(5):395-402. PubMed ID: 15448665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.